Fibrobiologics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on January 23, 2025, by Fibrobiologics, Inc. (FBLG), a Delaware corporation listed on the Nasdaq Global Market. The filing addresses Item 5.02 regarding the determination of annual incentive bonuses for Named Executive Officers (NEOs) for the fiscal year ended December 31, 2024. This disclosure updates a prior Form S-1 Registration Statement filed on January 10, 2025, which noted that these bonus amounts were pending determination.
Key Financial Metrics
The filing does not provide company-wide revenue, profit, cash flow, margins, debt, or liquidity metrics. The financial data presented is limited to executive compensation for the fiscal years 2023 and 2024.
| Executive Officer | Position | 2024 Total Compensation ($) | 2023 Total Compensation ($) |
|---|---|---|---|
| Pete O'Heeron | Chairperson and CEO | 1,805,199 | 4,286,308 |
| Hamid Khoja, Ph.D. | Chief Scientific Officer | 853,646 | 1,307,758 |
| Ruben A. Garcia | General Counsel | 2,752,843 | N/A |
Additional Compensation Details:
- Interim CFO Bonus: The Board approved a $75,000 bonus for Robert E. Hoffman, Interim Chief Financial Officer.
- Option Awards: Significant portions of 2024 compensation for Mr. O'Heeron ($788,452) and Mr. Garcia ($2,283,274) consist of stock option awards valued at grant date fair value per ASC 718.
- Non-Equity Incentives: Fiscal 2024 incentive bonuses were $390,000 for Mr. O'Heeron, $150,000 for Dr. Khoja, and $142,188 for Mr. Garcia.
Material Changes Versus Prior Period
Total compensation for the CEO and Chief Scientific Officer decreased significantly in 2024 compared to 2023, primarily due to a reduction in the value of stock option awards granted. Conversely, Mr. Garcia, who joined the company in March 2024, received substantial compensation in his first partial year, driven largely by option awards valued at $2,283,274.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of specific risks and contingencies beyond the standard disclosure of executive compensation. The document serves strictly to update the Summary Compensation Table following the Board's approval of 2024 bonuses.
Key Facts for Investor Verification
- Verify the valuation assumptions for the 2024 stock option grants, specifically the $2.36 exercise price and 108.93% annual volatility used for Mr. O'Heeron and Dr. Khoja.
- Confirm the impact of the $75,000 bonus for the Interim CFO on the company's cash burn rate, as this figure is not included in the NEO table.
- Review the full Form S-1 (File No. 333-284077) to understand the context of the capital raise and how executive compensation aligns with the company's fundraising goals.
- Note that Mr. Garcia's 2024 compensation includes $18,406 in relocation expenses and $15,525 in 401(k) matching, which are not present for other NEOs.